Cipro

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

China’s energy crunch threatens pharma supply chains

This week, PharmaCompass looks at the energy crunch in China and its likely fallout on the global

Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend

In less than three weeks, Donald Trump will assume office as the President of the United States. He

GSK, Google form first bioelectronics firm; 11 generic companies benefit from the Teva Allergan deal

This week, Phispers brings to you the details of the bioelectronics firm formed by GSK and Google. T

Phispers: Pfizer-Allergan end megamerger, GSK wants to make copying its drugs easier & more

This week, the biggest news in the world of pharmaceuticals was the termination of the Pfizer-Allerg

Antibiotic resistant superbugs: deadlier than cancer and closer to you than you think

The global war on superbugs, bacteria that grow resistant to drugs, infect humans and defy conventio

Haunted: Teva’s $1.2 billion ‘pay-for-delay’ penalty; which companies will get hit next?

Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total payment of

Dr. Reddy’s expansion plans for API production

Unrelated to the inspection of the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe